Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
04/2010
04/01/2010US20100080812 Antibodies against human IL17 and uses thereof
04/01/2010US20100080811 Anti-myostatin antibodies
04/01/2010US20100080810 Methods of treating diseases with anti-vegf antibodies
04/01/2010US20100080809 Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof
04/01/2010US20100080808 Anti-notch2 antibodies and methods of use
04/01/2010US20100080807 Methods and Compositions for Treating Viral Hemorrhagic Fever
04/01/2010US20100080806 Anti-human trail receptor dr5 monoclonal antibody (ad5-10), method thereof and use of the same
04/01/2010US20100080805 Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
04/01/2010US20100080804 Methods of treating inflammatory disorders of the lungs
04/01/2010US20100080803 Labor biomarkers, methods comprising same, and methods targeting same
04/01/2010US20100080802 Anti-il-tif antibodies and methods of use
04/01/2010US20100080801 Comprises nucleotide sequences coding antibody receptor for treating autoimmune and immunological diseases
04/01/2010US20100080800 Humanized antibody
04/01/2010US20100080799 Wstf regulates the dna damage response of h2a.x via novel tyrosine kinase activity
04/01/2010US20100080798 Kim-1 antagonists and use to modulate immune system
04/01/2010US20100080797 Therapy procedure for drug delivery for trigeminal pain
04/01/2010US20100080796 Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
04/01/2010US20100080795 Biodegradable thermogelling polymer
04/01/2010US20100080794 Mutant polypeptide having effector function
04/01/2010US20100080793 DcR3 polypeptide, A TNFR homolog
04/01/2010US20100080792 Method for Identifying a MHC Class II-Dependent Tumor-Associated T Helper Cell Antigen
04/01/2010US20100080776 Method of enhancing an immune response
04/01/2010US20100080773 Orally Bioavailable Lipid-Based Constructs
04/01/2010US20100080769 Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies
04/01/2010CA2775062A1 Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers
04/01/2010CA2738769A1 Vaccine adjuvants
04/01/2010CA2738756A1 Plasmodium vaccines, antigens, compositions, and methods
04/01/2010CA2738755A1 Individual 5-fluorouracile dose optimization in folfiri treatment
04/01/2010CA2738598A1 Composition for treating disease
04/01/2010CA2738485A1 Frizzled-binding agents and uses thereof
04/01/2010CA2738252A1 Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
04/01/2010CA2738033A1 Non-natural amino acid replication-dependent microorganisms and vaccines
04/01/2010CA2738024A1 Methods for purification of viruses
04/01/2010CA2738022A1 Methods for cultivating cells, propagating and purifying viruses
04/01/2010CA2737519A1 Anti-cd147 antibodies, methods, and uses
03/2010
03/31/2010EP2169073A1 Vector for the preparation of immunotherapeutical compositions
03/31/2010EP2169060A1 Novel polypeptide useful for diagnosis and treatment of cancer
03/31/2010EP2169054A1 Vaccine for swine edema disease
03/31/2010EP2168984A1 Human antibodies that bind human IL-12 and methods for producing
03/31/2010EP2168978A2 Amino acid and nucleic acid sequences and vaccine to control ectoparasite infestations in fish
03/31/2010EP2168977A1 Vaccine antigen capable of inducing cross-reacting and neutralizing antibody against high-risk-type human papillomavirus
03/31/2010EP2168599A1 Cancer remedy containing antibody against peptide encoded by exon-17 of periostin
03/31/2010EP2168598A1 Method of Treatment Using Ligand-Immunogen Conjugates
03/31/2010EP2168597A1 Vaccines comprising aluminium adjuvants and histidine
03/31/2010EP2168596A2 Immunisation against chlamydia trachomatis
03/31/2010EP2168595A1 Pharmaceutical compositions containing the protein nmb1796
03/31/2010EP2168594A1 Treating neoplasms with neurotoxin
03/31/2010EP2168593A1 Oral vaccine compositions
03/31/2010EP2168581A2 Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
03/31/2010EP2167664A1 Hybrid operon for expression of colonization factor (cf) antigens of enterotoxigenic escherichia coli
03/31/2010EP2167649A1 Immunotherapy for hematological malignancies
03/31/2010EP2167543A1 Antigen binding proteins that bind par-2
03/31/2010EP2167542A1 Neutralizing monoclonal antibody against human dll4
03/31/2010EP2167541A2 The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases
03/31/2010EP2167537A2 Compiled methods for analysing and sorting samples
03/31/2010EP2167536A1 Mhc multimers, methods for their generation, labeling and use
03/31/2010EP2167531A2 Streptococcus pneumoniae pilus antigens
03/31/2010EP2167528A2 Modified toxins
03/31/2010EP2167480A2 Cationic lipids compositions and methods for enhancing immune responses to vaccines
03/31/2010EP2167137A1 Hpv polyepitope constructs and uses thereof
03/31/2010EP2167130A2 Binding peptides having a c-terminally disposed specific binding domain
03/31/2010EP2167129A2 Compounds and methods for the treatment of renal disease
03/31/2010EP2167128A2 Engineered anti-alpha v- integrin hybrid antibodies
03/31/2010EP2167127A1 Novel formulation
03/31/2010EP2167125A1 An antibody specific for the tn antigen for the treatment of cancer
03/31/2010EP2167124A1 The use of monomycolyl glycerol (mmg) as an adjuvant
03/31/2010EP2167121A1 Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
03/31/2010EP2167120A2 Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
03/31/2010EP2167119A1 Chemically modified peptides with improved immunogenicity
03/31/2010EP2167113A2 Neuroplastin derived peptides
03/31/2010EP2167101A2 Antibodies and sirna against growth hormone, prolactin and proliferin for use in the treatment of tumors and endometriosis
03/31/2010EP2166844A1 Reduced-mass, long-acting dosage forms
03/31/2010EP1838343B1 Prrs vaccines
03/31/2010EP1549353B1 Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
03/31/2010EP1536820B1 Cancer therapy using whole glucan particles and antibodies
03/31/2010EP1530724B1 Diagnosis and prevention of cancer cell invasion
03/31/2010EP1251869B1 Immunogenic live rotavirus compositions with reduced risk of side effects
03/31/2010EP1194168B1 Methods and products for manipulating uncoupling protein expression
03/31/2010EP1107989B1 Expression and export of angiostatin and endostatin as immunofusins
03/31/2010CN101688871A Methods for measuring platelet reactivity of patients that have received drug eluting stents
03/31/2010CN101688867A methods and biomarkers for diagnosing and monitoring psychotic disorders
03/31/2010CN101688211A Hybrid operon for expression of colonization factor (cf) antigens of enterotoxigenic escherichia coli
03/31/2010CN101688200A Sequence based engineering and optimization of single chain antibodies
03/31/2010CN101688194A Detoxified pneumococcal neuraminidase and uses thereof
03/31/2010CN101688183A Cancerous disease modifying antibodies
03/31/2010CN101688179A Recombinant protein production in avian ebx r cells
03/31/2010CN101687932A Binding members for ige molecules
03/31/2010CN101687931A an anti-cancer cytotoxic monoclonal antibody
03/31/2010CN101687929A Monoclonal antibodies against claudin-18 for treatment of cancer
03/31/2010CN101687926A neutralizing antibodies
03/31/2010CN101687925A engineered anti-il-23p19 antibodies
03/31/2010CN101687924A anti-muc17 antibody
03/31/2010CN101687923A The ed-a antigen of fibrinogen associated with the neovasculature of tumour metastases
03/31/2010CN101687922A methods of treating ophthalmic diseases
03/31/2010CN101687919A Methods of treating RSV infections and related conditions
03/31/2010CN101687915A Cross-species-specific cd3-epsilon binding domain
03/31/2010CN101687908A Antigen determinant of rheumatoid arthritis-specific autoantibody and use thereof
03/31/2010CN101687900A Double-stranded locked nucleic acid compositions
03/31/2010CN101687049A Immunocytokines for cancer treatment in combination with chemotherapeutic agents
03/31/2010CN101687039A Engineered anti-alpha v- integrin hybrid antibodies
1 ... 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 ... 1823